CD274 and cancer: Although IFNα is not individually used for cancer treatment anymore due to its systematic side effects, its large impacts on the immune system hold immense potential for IFNα to elicit a cytotoxic immune response thus serving as a promising adjuvant agent with PD-1/PD-L1 inhibitors (16, 30).